Iovance Biotherapeutics
IOVA
IOVA
272 hedge funds and large institutions have $3.22B invested in Iovance Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 90 increasing their positions, 82 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
16% more funds holding
Funds holding: 235 → 272 (+37)
10% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 82
4.68% less ownership
Funds ownership: 82.45% → 77.77% (-4.7%)
Holders
272
Holding in Top 10
8
Calls
$93.8M
Puts
$31.4M
Top Buyers
| 1 | +$108M | |
| 2 | +$74.1M | |
| 3 | +$59.3M | |
| 4 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$44M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$43.7M |
Top Sellers
| 1 | -$89.2M | |
| 2 | -$70.2M | |
| 3 | -$40.4M | |
| 4 |
O
OrbiMed
New York
|
-$38.3M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$29.4M |